DJ Edison Investment Research Limited: Edison issues outlook on SymBio Pharmaceuticals (4582)
Edison Investment Research Limited
Edison Investment Research Limited: Edison issues outlook on SymBio
Pharmaceuticals (4582)
10-Sep-2020 / 08:46 GMT/BST
London, UK, 10 September 2020
Edison issues outlook on SymBio Pharmaceuticals (4582)
SymBio is approaching a major transition as it prepares to begin internal
marketing of its lead product Treakisym (bendamustine), launch new liquid
formulations of the drug and expand the market with new indications. At the
same time, the company is moving past the recent clinical results from the
Phase III study where rigosertib did not meet its primary endpoint and is
determining the future direction of its pipeline product brincidofovir. We
are taking this time to provide our clinical and commercial outlook.
We have lowered our valuation to ¥37.6bn or ¥1,068 per share from ¥39.0bn or
¥1,144 per share. This was driven by removing rigosertib from our models.
Additionally, we have adjusted brincidofovir for the new AdV indication,
which increased this program's valuation to ¥1,062m from ¥882m.
Click here [1] to view the full report.
Subscribe [2]to Edison's content to receive reports by email.
All reports published by Edison are free-to-access and available on the
website [3].
About Edison: Edison is an investment research and advisory company, with
offices in North America, Europe, the Middle East and AsiaPac. The heart of
Edison is our world-renowned equity research platform and deep multi-sector
expertise. At Edison Investment Research, our research is widely read by
international investors, advisers and stakeholders. Edison Advisors
leverages our core research platform to provide differentiated services
including investor relations and strategic consulting.
Edison is authorised and regulated by the Financial Conduct Authority [4].
Edison is not an adviser or broker-dealer and does not provide investment
advice. Edison's reports are not solicitations to buy or sell any
securities.
For more information please contact Edison:
Nathaniel Calloway, +1 646 653 7036
Wiktoria O'Hare, +1 646 653 7028
healthcare@edisongroup.com
Learn more at www.edisongroup.com [5] and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-group- [6]
Twitter www.twitter.com/Edison_Inv_Res [7]
YouTube www.youtube.com/edisonitv [8]
Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.
End of Announcement - EQS News Service
1129795 10-Sep-2020
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=7429138e4346e54eab64b13589e7f560&application_id=1129795&site_id=vwd&application_name=news
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=dc4b6da9609a3fa15934b7007f0912b2&application_id=1129795&site_id=vwd&application_name=news
3: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=2d62d350e44141e01d1766d8ed0b3f95&application_id=1129795&site_id=vwd&application_name=news
4: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=105fe9be9b5e36892886e5a39d51d4b7&application_id=1129795&site_id=vwd&application_name=news
5: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=88c95533002fab2316572f9ef6cf3cc6&application_id=1129795&site_id=vwd&application_name=news
6: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=afe662765000a80ab72afd922939c992&application_id=1129795&site_id=vwd&application_name=news
7: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=ec2d264fe4f303e2143a2e85c6eaa823&application_id=1129795&site_id=vwd&application_name=news
8: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=6b959e4d7ee3c402b931a274d2bbe945&application_id=1129795&site_id=vwd&application_name=news
(END) Dow Jones Newswires
September 10, 2020 03:46 ET (07:46 GMT)
© 2020 Dow Jones News
